Antimicrobial susceptibility of the bloodstream infections: A study in a nonteaching hospital;Estudio de sensibilidad antibiótica en las bacteriemias de un hospital secundario

Anales de Medicina Interna

Volumn 21, Issue 10, 2004, Pages 483-487

  Pazos Anon R ^a,d   Fernandez Rodriguez R ^a   Tinajas, A ^b   Nanin C ^a   Bustillo, M ^a   Paz, I ^b   Barreiro, R ^a   Gayoso Diz, P ^c  

^a Servicio de Medicina Interna   (Spain)

^b Servicio de Microbiología   (Spain)

^c Unidad de Investigacion   (Spain)

^d NONE   (Portugal)

Author keywords

Antimicrobial susceptibility; Bloodstream; Mortality

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CANDIDA; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; STAPHYLOCOCCUS;

DRUG RESISTANCE, MICROBIAL; HOSPITALIZATION; HUMANS; SEPSIS; SPAIN;

EID: 8844228925     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Weinstein MP, Towns ML, Quartey SM, Mirret S, Reimer LG, Parmigiani G, Reller B. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of microbiology, epidemiology and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24: 584-602.
2. Pfaller MA, Jones RN, Doren GV, Kugler K and The SENTRY Participants Group. Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother July 1998; 42: 1762-70.
3. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from in-patients and out-patients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-5.
4. Ballow C.H and Schentag JJ Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance. Group Diagn Microbiol Infect Dis 1992; 15: 37S-42S.
5. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 1996, 275: 300-4.
6. Pazos R, Fernández R, Paz I, Tinajas A, Cantón I, Abel V, González R, Martínez R, Gayoso P. Factores pronósticos de bacteraemia: estudio prospective. An Med Interna (Madrid) 2001; 18: 41-6.
7. National Committee for Clinical Laboratory Standards (NCLSS). Performance standards for antimicrobial susceptibility testing. Supplement tables. NCCLS document M100-S8. Wayne, PA: NCCLS 1998 Mc Cabe WR, Jackson GG. Gram negative bacteremia. Etiology and ecology. Arch Intern Med 1962; 110: 847-55.
8. Vázquez F, Mendoza MC, Villar MH, Pérez F, Méndez FJ. Survey of bacteraemia in a Spanish Hospital over a decade (1981-1990). J Hosp Infect 1994; 26: 111-21.
9. Archibald L, Jones RN. The emergent needs for basic research, education and surveillance of antimicrobial resistance. Diagn Microbiol Infect Dis 1996; 25: 1-9.
10. Centres for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin- United states, 1989-1993- MMWR Morb Mortal Wkly Rep 1993; 42: 597-9.
11. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J, and the SENTRY participants Group. Antimicrobial Susceptibility and Frequency of Occurrence of Clinical Blood Isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin Infec Dis 2000, 456-60.
12. Johnson LB, Bhan A, Pawlak J, Manzor O, Saravolatz LD. Changing epidemiology of community-onset methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003; 24 (6): 431-5.
13. Hofmann J, Cetron MS, Farley MM, Baugman WS, Facklam RR, Elliott JA, et al. The prevalence of drug ressitant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 33: 481-6
14. Mutnick AH, Biedenbach DJ, Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in th SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbial Infect Dis 2003; 46 (1): 63-8.
15. Monnet D, Edwards J, Gaynes R, the National Nosocomial Infections Surveillance System. Extended spectrum beta-lactam-resistant nosocomial Klebsiella pneumoniae: epidemiologic evidence of interhospital transmission (abstract no 24. In: program of the 4th annual meeting of the Society for Healthcare Epidemiology of America (New Orleans. Thorofare, NJ: SLACK, 1994: 23).
16. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SGB, Gould IM. Emergence of acquired carbapenem-resistant Klebsiella pneumoniae (letter). Lancet 1997; 351: 783.
17. Edwards JE Jr, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in non neutropenic patients. Clin Infect Dis 1992; 14 (Supl. 1): S 106-13
18. Pittet D, Garbino J. Fungal infections in the critically ill. Curr Opin Crit Care 1995; 1: 369-80
19. Winston DJ, Dudnick DV, Chapin M. Coagulase-negative staphycoccal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 1983; 143: 32-6.
20. Domínguez de Villota E, Algora-Weber A, Millian I, Rubio JJ, Galdos P, Mosquera JM. Early evaluation of coagulase negative staphylococcus in blood samples of intensive care unit patients. A clinically uncertain judgement. Intensive Care Med 1987; 13: 390-4.
21. Kollef MH. Inadequate antimicrobial treatment: an important determination of outcome for hospitalised patients. Clin Infect Dis 2000; 31 (Supl. 4): S 131-8.